The Department of Health and Human Services offers the BARDA Special Projects Grant to support advanced development of medical countermeasures for various threats. BARDA has a successful track record in acquiring FDA-approved products and responding to emerging health crises like pandemics and epidemics. This grant aims to address challenges in developing medical countermeasures against emerging threats such as antimicrobial resistance. By engaging external experts to provide technical recommendations, BARDA seeks to expedite the development of effective solutions. Applicants have the opportunity to contribute to national health security by innovating in the field of medical countermeasure development. Closing date: September 4, 2015.
Opportunity ID: 277681
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 7 |
| Posted Date: | Jul 06, 2015 |
| Last Updated Date: | Jul 13, 2015 |
| Original Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | County governments Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Individuals Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) State governments City or township governments Special district governments For profit organizations other than small businesses Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDAÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nationÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Jul 13, 2015 | ||
| removing characters | Jul 13, 2015 | |
| Jul 13, 2015 | ||
| Removed URL | Jul 08, 2015 | |
| Jul 08, 2015 | ||
| Text Description revision | Jul 07, 2015 | |
| Jul 06, 2015 |
DISPLAYING: Synopsis 7
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 7 |
| Posted Date: | Jul 06, 2015 |
| Last Updated Date: | Jul 13, 2015 |
| Original Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | County governments Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Individuals Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) State governments City or township governments Special district governments For profit organizations other than small businesses Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDAÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nationÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 6
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 6 |
| Posted Date: | Jul 13, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Native American tribal governments (Federally recognized) Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Individuals Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally.BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDA purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nations response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 5
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 5 |
| Posted Date: | Jul 13, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Native American tribal governments (Federally recognized) Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Individuals Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDAÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nationÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 4
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 4 |
| Posted Date: | Jul 08, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally.BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDA’s purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nation’s response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Jul 08, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Native American tribal governments (Federally recognized) Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Individuals Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDAÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nationÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jul 07, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Native American tribal governments (Federally recognized) Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Individuals Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally.BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDA’s purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nation’s response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDA’s purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nation’s response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-15-002 |
| Funding Opportunity Title: | The Biomedical Advanced Research and Development Authority Special Projects |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 06, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 04, 2015 Application Deadline Date: September 4, 2015 at 11:59pm EST |
| Archive Date: | Oct 04, 2015 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $200,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Native American tribal governments (Federally recognized) Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Individuals Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Non-domestic (non-U.S.) entity – Unless the authorizing legislation under which an award would be made specifically authorizes awards to foreign entities or the grant is for research (not research-related grants), foreign entities are not eligible for HHS grants |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), supports advanced development and availability of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases through advanced product development, stockpile acquisition, building manufacturing infrastructure, and product innovation. BARDA establishes and maintains business collaborations by means of grants, cooperative agreements, contracts, and other transactions with the public and private sectors, domestically and internationally. BARDA has grown significantly since inception, acquiring new capabilities and employing new business approaches leading to unprecedented success in the development and acquisition of MCMs. Twenty-one products supported by BARDA have received FDA approval, licensure or clearance against the threats within BARDAÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs purview and twelve products have been procured under Project BioShield for the Strategic National Stockpile. BARDA has also played a key role in responding to newly emerging threats, including most prominently the 2009-H1N1 influenza pandemic as well as the ongoing Ebola epidemic in West Africa. The National Strategy for Combating Antibiotic Resistant Bacteria (2014) identifies BARDA as having a key role in the nationÃÂÃÂÃÂÃÂÃÂÃÂÃÂâÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂs response to the more slowly, but inexorably emerging threat of antimicrobial resistance (AMR). By their unpredictability and potentially explosive nature, emerging threats present unique challenges, particularly with respect to the development of MCMs, which normally takes years, requires substantial investment, and is associated with high rates of attrition. Many of the challenges are technical; some are economic. The problem of AMR presents special hurdles in that the discovery of novel drug targets unique to the resistant pathogens has proved increasingly difficult. Having a mechanism in place to engage external subject matter experts and develop far-reaching, but focused, technical reports that provide recommendations on how to address such challenges would facilitate progress in the development of MCMs against these national health security threats. |
| Link to Additional Information: | The Biomedical Advanced Research and Development Authority Special Projects |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
Related Documents
Folder 277681 Full Announcement-1 -> final foa july 8 2015.pdf
Folder 277681 Full Announcement-2 -> technical assistance conference call july 17 2015.pdf
Folder 277681 Full Announcement-3 -> question and answer august 3 2015.pdf
Folder 277681 Other Supporting Documents-Questions and Answers 1 -> q and a aug 19 2015.pdf
Packages
| Agency Contact Information: | Grants.gov Contact Center Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email: support@grants.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.360 | EP-IDS-15-002-054377 | The Biomedical Advanced Research and Development Authority Special Projects | PKG00217742 | Jul 06, 2015 | Sep 04, 2015 | View |
Package 1
Mandatory forms
277681 SF424_2_1-2.1.pdf
277681 Project_Abstract-1.1.pdf
277681 SF424A-1.0.pdf
277681 SF424B-1.1.pdf
Optional forms
277681 Project-1.1.pdf
277681 Budget-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
